The Cancer Drugs Fund

DRUG

INDICATION

YES/ NO/ CDF

Abiraterone

metastatic castration resistant prostate cancer

Albumin Bound Paclitaxel

advanced adenocarcinoma of the pancreas

Bendamustine

Chronic Lymphocytic Leukaemia OR low grade lymphoma OR mantle cell non-Hodgkin’s lymphoma OR relapsed multiple myeloma

Bevacizumab

recurrent or metastatic cervical cancer OR advanced breast cancer OR advanced colorectal cancer OR low grade gliomas of childhood OR advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer

Bortezomib

bortezomib naive relapsed multiple myeloma

Bosutinib

(Bosulif, Pfizer)

refractory chronic/ accelerated phase Chronic Myeloid Leukaemia

 YES

Routine NHS use

Brentuximab

refractory systemic anaplastic lymphoma OR relapsed or refractory CD30+ Hodgkin’s lymphoma

Cabazitaxel

castrate-resistant Metastatic Prostate Cancer

Cabozantinib

medullary thyroid cancer

Ceritinib (Zykadia, Novartis)

previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer

YES

Routine NHS use

Cetuximab  (Erbitux, Merck)

head and neck cancer OR metastatic colorectal cancer 

NO

Not cost-effective

Clofarabine

acute lymphoblastic leukaemia OR acute myeloblastic leukaemia

Crizotinib (Xalkori, Pfizer)

non-small cell lung cancer

YES

Routine NHS use

Dasatinib

Ph+ acute lymphoblastic leukaemia OR chronic/ accelerated phase chronic myeloid leukaemia

Enzalutamide

Metastatic Prostate Cancer

Eribulin (Halaven, Eisai)

advanced breast cancer

YES

Routine NHS use

Everolimus (Novartis)

advanced breast cancer AND renal cell carcinoma

YES

Routine NHS use

Ibrutinib

Chronic Lymphocytic Leukaemia OR Mantle Cell Lymphoma

Idelalisib

Chronic Lymphocytic Leukaemia

Lenalidomide

myelodysplastic syndromes (MDS) OR multiple myeloma

Nelarabine

T-cell acute lymphoblastic leukaemia OR refractory T-cell lymphoblastic non-Hodgkin’s lymphoma

Nivolumab (Opdivo, Bristol-Myers Squibb)

squamous and non-squamous advanced non-small-cell lung cancer

Case was not clear cut then YES

Routine NHS use

Ofatumumab

chronic lymphocytic leukaemi

Osimertinib (Tagrisso, AstraZeneca)

lung cancer

YES

Only on CDF

Panitumumab

metastatic colorectal cancer

Pegylated Liposomal Doxorubicin

Named sarcomas

Pemetrexed

(Alimta, Eli Lilly)

non-squamous non-small cell lung cancer

YES 

NHS routine use

Peptide Receptor Radionucleotide Therapy (Octreotate)

neuroendocrine tumours

Pertuzumab

locally advanced or metastatic breast cancer

Pomalidomide

relapsed and refractory multiple myeloma

Ponatinib

(Iclusig, Incyte Corporation)

Chronic Myeloid Leukaemia with T315I Mutation OR Ph+ Acute Lymphoblastic Leukaemia with T315I Mutation

YES

NHS routine use

Radium-223 Dichloride

castration-resistant prostate cancer

Regorafenib

gastro-intestinal stromal tumours (GIST)

Ruxolitinib

symptomatic splenomegaly in primary myelofibrosis OR post polycythaemia vera myelofibrosis OR post essential thrombocythaemia myelofibrosis

Sorafenib

hepatocellular carcinoma OR papillary or follicular thyroid cancer

Sunitinib

pancreatic neuroendocrine carcinomas

Temsirolimus

renal cell carcinoma

Trastuzumab Emtansine

HER2-positive locally advanced/ unresectable OR metastatic (Stage IV) breast cancer

Vandetinib

medullary thyroid cancer

Vismodegib

locally advanced or metastatic Basal Cell Carcinoma